Valneva SE
NASDAQ:VALNBiotechnology
+$0.01 today
- Market cap
- $507.98M
- Beta
- 1.40
- P/E (TTM)
- -2.9
- EPS (TTM)
- -$0.80
Volume 0.00M
Average 0.09M
VALN Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Valneva SENASDAQ: VALN
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development grows, but more slowly than its trailing trend
Q1 FY2026 research & development of €15.22M rose 1.8% year over year, behind the +12.6% change in trailing-twelve-month research & development. Sequentially, it fell 40.5% from the prior quarter. Over 3 fiscal years it compounded at -6.7% a year.
Context
- Research & development amounted to 48.8% of revenue in FY2025, up 5.1 pp from a year earlier.
- Research & development increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from +1.8% toward the trailing-twelve-month pace of +12.6%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
EUR · from the income statement
- Latest · FY2025
- 85.3M EUR
- Year-over-year change
- +15.1%
- 4-year CAGR
- -16.2%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 85.3M | +15.1% |
| FY2024 | 2024-12-31 | 74.14M | +23.8% |
| FY2023 | 2023-12-31 | 59.89M | -42.9% |
| FY2022 | 2022-12-31 | 104.92M | -39.5% |
| FY2021 | 2021-12-31 | 173.28M | — |
Research & Development vs competitors
How VALN compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +12.6% is the 3rd highest of 8, against a peer median of -15.0%.
- Research & development amounts to 54.7% of revenue for VALN, versus a peer median of 138.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $2.66B USD | -23.6% | -1.7% | 105.3% | |
| LTM Jun 2026 | $1.03B USD | +74.2% | +67.4% | — | |
| LTM Mar 2026 | $446.24M USD | -15.0% | -3.0% | 681.3% | |
| LTM Mar 2026 | $345.36M USD | -10.9% | -35.2% | 57.9% | |
| LTM Sep 2026 | $252.23M USD | +33.2% | -5.7% | 138.2% | |
| LTM Mar 2026 | $98.25M USD | -44.3% | -8.8% | 216.6% | |
| LTM Mar 2026 | €85.57M EUR | +12.6% | -6.7% | 54.7% | |
| LTM Mar 2026 | $51.51M USD | -27.2% | -33.9% | — | |
| Peer median (excluding VALN) | — | -15.0% | -5.7% | 138.2% | |
Competitors are the stored peer set for VALN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 348.09M | 361.3M | 153.71M | 169.58M | 174.66M |
| Cost of Revenue | 187.92M | 324.44M | 100.88M | 98.54M | 107.14M |
| Gross Profit | 160.17M | 36.86M | 52.84M | 71.04M | 67.52M |
| Gross Margin | 46.0% | 10.2% | 34.4% | 41.9% | 38.7% |
| Research & Development | 173.28M | 104.92M | 59.89M | 74.14M | 85.3M |
| Selling, General & Admin | 71.25M | 57.58M | 96.55M | 95.11M | 74.68M |
| Operating Expenses | 221.56M | 150.31M | 134.92M | 57.71M | 149.15M |
| Depreciation & Amortization | 14.28M | 21.04M | 17.58M | 19.59M | 21.75M |
| EBITDA | (38.74M) | (104.73M) | (57.72M) | 32.08M | (50.47M) |
| EBITDA Margin | -11.1% | -29.0% | -37.6% | 18.9% | -28.9% |
| Operating Income | (61.39M) | (113.44M) | (82.09M) | 13.33M | (81.63M) |
| Operating Margin | -17.6% | -31.4% | -53.4% | 7.9% | -46.7% |
| Interest Income | 249K | 260K | 1.21M | 2.36M | 1.8M |
| Interest Expense | 16.96M | 19.05M | 23.33M | 23.98M | 41.9M |
| Other Income / Expenses | (8.59M) | (31.37M) | (16.54M) | (24.82M) | (32.49M) |
| Income Before Tax | (69.98M) | (144.82M) | (98.63M) | (11.49M) | (114.12M) |
| Pre-Tax Margin | -20.1% | -40.1% | -64.2% | -6.8% | -65.3% |
| Income Tax Expense | 3.45M | (1.54M) | 2.8M | 761K | 1.07M |
| Net Income | (73.43M) | (143.28M) | (101.43M) | (12.25M) | (115.19M) |
| Net Margin | -21.1% | -39.7% | -66.0% | -7.2% | -66.0% |
| EPS (Basic) | (1.50) | (2.48) | (1.46) | (0.17) | (1.32) |
| EPS (Diluted) | (1.50) | (2.48) | (1.46) | (0.17) | (1.32) |
| Weighted Avg Shares | 48.81M | 57.74M | 69.47M | 70.26M | 84.09M |
| Weighted Avg Shares (Diluted) | 48.81M | 57.74M | 69.31M | 70.26M | 84.09M |
Valneva SE
NASDAQ:VALN
Intrinsic Alpha fair value
Locked
Current Price
$5.34
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.